Synthesis of ranolazine metabolites and their anti-myocardial ischemia activities

Chemical and Pharmaceutical Bulletin

Volumn 57, Issue 11, 2009, Pages 1218-1222

  Yao, Zhangyu ^a   Gong, Shubo ^a   Guan, Teng ^a   Li, Yunman ^a   Wu, Xiaoming ^a   Sun, Hongbin ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Metabolite; Myocardial ischemia; R R interval; Ranolazine; T wave

Indexed keywords

1 [(2,6 DIMETHYLPHENYL)AMINOCARBONYLMETHYL] 4 [2,3 DIHYDROXYLPROPYL]PIPERAZINE; 1 [3 (2 HYDROXYLPHENOXY) 2 HYDROXYPROPYL] 4 [N (2,6 DIMETHYLPHENYL)AMINOCARBONYLMETHYL]PIPERAZINE; 1 [3 (2 METHOXYPHENOXY) 2 HYDROXYPROPYL]PIPERAZINE; 2 HYDROXYL 3 (2 METHOXYPHENOXY)PROPIONIC ACID; CVT 2512; CVT 2513; CVT 2514; CVT 2738; CVT 4786; FATTY ACID; GLUCOSE; ISOPRENALINE; N (2,6 DIMETHYLPHENYL) 1 PIPERAZINE ACETAMIDE; PYRUVATE DEHYDROGENASE; RANOLAZINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG SYNTHESIS; ELECTROCARDIOGRAM; FATTY ACID OXIDATION; FEMALE; GLUCOSE OXIDATION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; MALE; METABOLITE; MOUSE; NONHUMAN; SYMPTOM;

ACETANILIDES; ANIMALS; CARDIOVASCULAR AGENTS; DRUG EVALUATION, PRECLINICAL; ELECTROCARDIOGRAPHY; FEMALE; GLUCOSE; ISOPROTERENOL; MALE; MICE; MICE, INBRED STRAINS; MYOCARDIAL ISCHEMIA; OXIDATION-REDUCTION; PIPERAZINES;

EID: 71049154222     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.57.1218     Document Type: Article

References (27)

1. Chagas A. C. P., Dourado P. M. M., Curr. Pharmaceut. Des., 14, 2563-2571 (2008).
2. McCormack J. G., Barr R. L., Wolff A. A., Lopaschuk G. D., Circulation, 93, 135-142 (1996).
3. Clarke B., Spedding M., Patmore L., McCormack J. G., Br. J. Pharmacol., 109, 748-750 (1993).
4. Gralinski M. R., Black S. C., Kilgore K. S., Chou A. Y., McCormack J. G., Lucchesi B. R., Cardiovasc. Res., 28, 1231-1237 (1994).
5. Gralinski M. R., Chi L., Friedrichs G. S., Tanhehco E. J., McCormack J. G., Lucchesi B. R., J. Cardiovasc. Pharmacol. Ther., 1, 141-148 (1996).
6. Clarke B., Wyatt K. M., McCormack J. G., J. Mol. Cell. Cardiol., 28, 341-350 (1996).
7. McCormack J. G., Stanley W. C., Wolff A. A., Gen. Pharmacol., 30, 639-645 (1998).
8. Collins-Nakai R. L., Barr R., Can. J. Cardiol., 9, Suppl. E, 33 (1933).
9. Gamble J., Collins-Nakai R. L., Can. J. Physiol. Pharmacol., 72, Suppl. I, 96 (1944).
10. Lopaschuk G. D., Wambolt R. B., Barr R. L., J. Pharmacol. Exp. Ther., 264, 135-144 (1993).
11. McCormack J. G., Stanley W. C., Wolff A. A., Gen. Pharmacol., 30, 639-645 (1998).
12. Pepine C. J., Wolff A. A., Am. J. Cardiol., 84, 46-50 (1999).
13. Zacharowski K., Blackburn B., Thiemermann C., Eur. J. Pharmacol., 418, 105-110 (2001).
14. Chaitman B. R., Skettino S. L., Parker J. O., Hanley P., Meluzin J., Kuch J., Wang W., Herbert D. A., Wolff A. A., J. Am. Coll. Cardiol., 43, 1375-1382 (2004).
15. Chu N., Lustig D., Wong S., Drug Metab. Rev., 35, 49 (2003).
16. Tafreshi M. J., Fisher B., Ann. Pharmacother., 40, 689-693 (2006).
17. Zerumsky K., Mcbride B. F., Am. J. Health-Syst. Pharm., 63, 2331-2338 (2006).
18. Herron W. J., Eadie J., Penmen A. D., J. Chromatogr. A., 712, 55-60 (1995).
19. Penman A. D., Eadie J., Herron W. J., Reilly M. A., Rush W. R., Rapid Commun. Mass Spectrom., 9, 1418-1430 (1995).
20. Lu W., Li Y., Zhao X., Guo C., Zhou K., Chin. J. Med. Chem., 35, 641-642 (2004).
21. Brimble M. A., Liu Y. C., Trzoss M., Synthesis, 9, 1392-1402 (2007).
22. Gant T. G., Sarshar S., US2008312247, (2008).
23. Bredikhina Z. A., Novikova V. G., Zakharychev D. V., Bredikhin A. A., Tetrahedron: Asymmetry, 17, 3015-3020 (2006).
24. Pickens C. L., Milliron A. R., Urology, 54, 24-27 (1999).
25. Xu S., Bian R., Chen X., Pharmacol. Test. Method, 31, 998-1022.
26. Li P., Evans C. D., Wu Y., Cao B., Hamel E., Joulfié M. M., J. Am. Chem. Soc., 130, 2351-2364 (2008).
27. Fan L., Yuan L., Chen Z., Ma C., China Pharm., 16, 176-177 (2005).